

36713
SEARCH NOTES FOR PCT/US04/367103 1/31/05
updated 7/8/05

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	2001wo-gb03694.ap,prai.	DERWENT	OR	OFF	2005/01/31 13:29
L2	0	2001wo-gb3694.ap,prai.	DERWENT	OR	OFF	2005/01/31 13:30
L3	1	2001wo-gb03694.ap,prai.	DERWENT	OR	OFF	2005/01/31 13:30
L4	0	wo-0215920-\$.did.	DERWENT	OR	OFF	2005/01/31 13:31
L5	0	wo-0215920-\$.did.	EPO; DERWENT	OR	OFF	2005/01/31 13:31
L6	3	"2003077297".did.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/01/31 14:23
L7	1	wo-200239983-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:24
L8	1	wo-200203962-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:26
L9	1	wo-200166081-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:30
L10	0	wo-199906046-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:31
L11	0	wo-199818610-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:31
L12	2	wo-9808610-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:32
L13	1	wo-9747285-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:33
L14	1	wo-2003084518-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:34
L15	1	wo-2003074034-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:35
L16	1	wo-2003020200-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:36
L17	0	wo-2000021525-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:36
L18	0	wo-0021525-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:36

L19	0	wo-00021525-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:36
L20	1	wo-200021525-\$.did.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:51
L21	2	"5376383".pn.	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:56
L22	0	solubiliz? and (release adj modulat?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 16:57
L23	1	solubiliz? and ("release modulator")	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:03
L24	484863	(polymer? adj matri?) or polymer? or wax? or (fatty adj alcohol?) or (fatty adj acid?) or tocol?	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:03
L25	488557	I24 or cellulose? or ?polymer? or polyvinylpyrrolidone? or shellac? or (polyvinyl adj acetate adj phthalate?) or (polysaccharide? adj gum?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:05
L26	490008	I25 or (microcrystalline adj wax?) or (hydrogenated adj vegetable adj oil) or (glycerol adj dibehenate?) or (glycerol adj distearate?) or (glycerol adj dipalmitate?) or (glycerol adj palmitostearate?) or (lauroyl adj macrogolglyceride?) or (stearoyl adj macrogol?) or (calcium adj steroyl adj lactylate) or (stearic adj acid?) or (stearoyl adj alcohol?) or (sucrose adj distearate?) or (sucrose adj palmitate?) or (sucrose adj dipalmitate?) or (yellow adj wax?) or (white adj wax?) or (carnauba adj wax?) or (nonionic adj emulsifying adj wax?) or (cetyl adj ester adj wax?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:09
L27	8	I26 and (pioglitazone? or zafirlukast? or simvastatin? or atorvastatin? or fenofibrate?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:27
L28	0	I26 and (pioglitazone? and zafirlukast? and simvastatin? and atorvastatin? and fenofibrate?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:24
L29	5601	(correlation adj coefficient)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:27

L30	0	I29 and (solubil?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:28
L31	1	I29 and pharmaceut?	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:34
L32	2461	drug adj release?	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:35
L33	0	I32 and I27	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:35
L34	0	I32 and (pioglitazone? or zafirlukast? or simvastatin? or atorvastatin? or fenofibrate? or carvedilol? or amiodarone? or dronedrone? or risperidone? or ziprasidone?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:37
L35	19	(pioglitazone? or zafirlukast? or simvastatin? or atorvastatin? or fenofibrate? or carvedilol? or amiodarone? or dronedrone? or risperidone? or ziprasidone?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:40
L36	19	(pioglitazone? or zafirlukast? or simvastatin? or atorvastatin? or fenofibrate? or carvedilol? or amiodarone? or dronedrone? or risperidone? or ziprasidone?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:41
L37	11383	tocopherol	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:41
L38	3391	tocopherol?	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:41
L39	5743	I37 and derivative?	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:42
L40	0	?tocopherol? adj (acetate? or nicotinoate? or succinate? or polyethyleneglycol?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:43
L41	49	tocopherol adj (acetate? or nicotinoate? or succinate? or polyethyleneglycol?)	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:53
L42	290	tocopherol adj ester?	USPAT; EPO; DERWENT	OR	OFF	2005/01/31 17:53

SEARCH NOTES FOR PCT/US04/36713
updated Search done 7/8/05

=> d que 131

L1 4 SEA FILE=REGISTRY ABB=ON PLU=ON PIOGLITAZONE?/CN
 L2 3 SEA FILE=REGISTRY ABB=ON PLU=ON ZAFIRLUKAST?/CN
 L3 0 SEA FILE=REGISTRY ABB=ON PLU=ON SIMIVASTATIN?/CN
 L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON ZOCOR/CN
 L5 7 SEA FILE=REGISTRY ABB=ON PLU=ON SIMVASTATIN?/CN
 L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON LIPITOR/CN
 L7 7 SEA FILE=REGISTRY ABB=ON PLU=ON ATORVASTATIN?/CN
 L8 2 SEA FILE=REGISTRY ABB=ON PLU=ON FENOFIBR?/CN
 L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON CILOSTAZOL?
 L11 24 SEA FILE=REGISTRY ABB=ON PLU=ON (L1 OR L2 OR L3 OR L4 OR L5
 OR L6 OR L7 OR L8 OR L9)
 L14 3015 SEA FILE=HCAPLUS ABB=ON PLU=ON SOLUBILIZERS+PFT,NT/CT
 L15 8725 SEA FILE=HCAPLUS ABB=ON PLU=ON "DRUG DELIVERY SYSTEMS (L)
 SUSTAINED-RELEASE"+PFT,OLD/CT
 L27 78 SEA FILE=REGISTRY ABB=ON PLU=ON (107753-78-6/CRN OR 111025-46
 -8/CRN OR 112529-15-4/CRN OR 121009-77-6/CRN OR 125995-03-1/CRN
 OR 134523-00-5/CRN OR 134523-01-6/CRN OR 134523-02-7/CRN OR
 134523-03-8/CRN OR 139893-43-9/CRN OR 145350-09-0/CRN OR
 151006-18-7/CRN OR 262291-01-0/CRN OR 262291-02-1/CRN OR
 340266-37-7/CRN OR 344423-98-9/CRN OR 414355-31-0/CRN OR
 42017-89-0/CRN OR 424787-67-7/CRN OR 468728-50-9/CRN OR
 49562-28-9/CRN OR 618116-61-3/CRN OR 73963-72-1/CRN OR
 79902-63-9/CRN)
 L28 89 SEA FILE=REGISTRY ABB=ON PLU=ON L27 OR L11
 L30 4249 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 (L) (BAC OR DMA OR PAC OR
 PKT OR THU)/RL
 L31 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L30 AND (L14 OR SOLUBILIZ?)
 AND (L15 OR (SUSTAIN? OR EXTEND?) (3A)RELEAS?)

=> d 131 ibib abs hitind 1-5

L31 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:675655 HCAPLUS
 DOCUMENT NUMBER: 141:195290
 TITLE: Dual release antidiabetic drugs
 INVENTOR(S): Thembalath, Ramachandran; Bansal, Yatish Kumar; Tawde,
 Vaishali Manish; Jadhav, Vivek Kamalakar
 PATENT ASSIGNEE(S): Ipca Laboratories Limited, India
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069229	A1	20040819	WO 2003-IN313	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

=> d que 149

L1 4 SEA FILE=REGISTRY ABB=ON PLU=ON PIOGLITAZONE?/CN
L2 3 SEA FILE=REGISTRY ABB=ON PLU=ON ZAFIRLUKAST?/CN
L3 0 SEA FILE=REGISTRY ABB=ON PLU=ON SIMIVASTATIN?/CN
L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON ZOCOR/CN
L5 7 SEA FILE=REGISTRY ABB=ON PLU=ON SIMVASTATIN?/CN
L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON LIPITOR/CN
L7 7 SEA FILE=REGISTRY ABB=ON PLU=ON ATORVASTATIN?/CN
L8 2 SEA FILE=REGISTRY ABB=ON PLU=ON FENOFIBR?/CN
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON CILOSTAZOL?
L11 24 SEA FILE=REGISTRY ABB=ON PLU=ON (L1 OR L2 OR L3 OR L4 OR L5
OR L6 OR L7 OR L8 OR L9)
L12 5280 SEA FILE=HCAPLUS ABB=ON PLU=ON L11
L14 3015 SEA FILE=HCAPLUS ABB=ON PLU=ON SOLUBILIZERS+PFT,NT/CT
L15 8725 SEA FILE=HCAPLUS ABB=ON PLU=ON "DRUG DELIVERY SYSTEMS (L)
SUSTAINED-RELEASE"+PFT,OLD/CT
L17 54 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L15
L27 78 SEA FILE=REGISTRY ABB=ON PLU=ON (107753-78-6/CRN OR 111025-46
-8/CRN OR 112529-15-4/CRN OR 121009-77-6/CRN OR 125995-03-1/CRN
OR 134523-00-5/CRN OR 134523-01-6/CRN OR 134523-02-7/CRN OR
134523-03-8/CRN OR 139893-43-9/CRN OR 145350-09-0/CRN OR
151006-18-7/CRN OR 262291-01-0/CRN OR 262291-02-1/CRN OR
340266-37-7/CRN OR 344423-98-9/CRN OR 414355-31-0/CRN OR
42017-89-0/CRN OR 424787-67-7/CRN OR 468728-50-9/CRN OR
49562-28-9/CRN OR 618116-61-3/CRN OR 73963-72-1/CRN OR
79902-63-9/CRN)
L28 89 SEA FILE=REGISTRY ABB=ON PLU=ON L27 OR L11
L30 4249 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 (L) (BAC OR DMA OR PAC OR
PKT OR THU)/RL
L31 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L30 AND (L14 OR SOLUBILIZ?)
AND (L15 OR (SUSTAIN? OR EXTEND?) (3A)RELEAS?)
L39 26 SEA FILE=REGISTRY ABB=ON PLU=ON POLYOXYETHYLENE-POLYOXYPROPYL
ENE?/CN
L40 207 SEA FILE=REGISTRY ABB=ON PLU=ON CYCLODEXTRIN?/CN
L41 21 SEA FILE=REGISTRY ABB=ON PLU=ON TOCOL?
L42 372 SEA FILE=REGISTRY ABB=ON PLU=ON "TOCOPHEROL"
L43 47020 SEA FILE=HCAPLUS ABB=ON PLU=ON (L39 OR L40 OR L41 OR L42)
L44 350120 SEA FILE=HCAPLUS ABB=ON PLU=ON FATTY ACIDS+PFT,NT/CT
L45 24013 SEA FILE=HCAPLUS ABB=ON PLU=ON FATTY ACIDS/CT(L)ESTER
L46 350120 SEA FILE=HCAPLUS ABB=ON PLU=ON L44 OR L45
L47 390009 SEA FILE=HCAPLUS ABB=ON PLU=ON L43 OR L46
L48 27 SEA FILE=HCAPLUS ABB=ON PLU=ON L30 AND L47 AND (L15 OR
(SUSTAIN? OR EXTEND? OR DELAY?) (3A)RELEAS? OR SYNCH?)
L49 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 NOT (L17 OR L31)

=> d 149 ibib abs hitind 1-9

L49 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:453026 HCAPLUS

DOCUMENT NUMBER: 141:12310

TITLE: Pharmaceutical compositions containing a
biguanide-glitzazone combination

INVENTOR(S): Trehan, Anupam; Madan, Sumit; Arora, Vinod Kumar;
Malik, Rajiv

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

=> d que 123

L1 4 SEA FILE=REGISTRY ABB=ON PLU=ON PIOGLITAZONE?/CN
L2 3 SEA FILE=REGISTRY ABB=ON PLU=ON ZAFIRLUKAST?/CN
L3 0 SEA FILE=REGISTRY ABB=ON PLU=ON SIMIVASTATIN?/CN
L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON ZOCOR/CN
L5 7 SEA FILE=REGISTRY ABB=ON PLU=ON SIMVASTATIN?/CN
L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON LIPITOR/CN
L7 7 SEA FILE=REGISTRY ABB=ON PLU=ON ATORVASTATIN?/CN
L8 2 SEA FILE=REGISTRY ABB=ON PLU=ON FENOFIBR?/CN
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON CILOSTAZOL?
L11 24 SEA FILE=REGISTRY ABB=ON PLU=ON (L1 OR L2 OR L3 OR L4 OR L5
OR L6 OR L7 OR L8 OR L9)
L12 5280 SEA FILE=HCAPLUS ABB=ON PLU=ON L11
L13 4248 SEA FILE=HCAPLUS ABB=ON PLU=ON L11(L) (BAC OR DMA OR PAC OR
PKT OR THU)/RL
L14 3015 SEA FILE=HCAPLUS ABB=ON PLU=ON SOLUBILIZERS+PFT,NT/CT
L15 8725 SEA FILE=HCAPLUS ABB=ON PLU=ON "DRUG DELIVERY SYSTEMS (L)
SUSTAINED-RELEASE"+PFT,OLD/CT
L16 48 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND L13
L17 54 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L15
L18 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L14
L19 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND L15
L22 48 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 OR L19
L23 54 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 OR L22

=> d 123 ibib abs.hitind 1-54

L23 ANSWER 1 OF 54 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1156434 HCAPLUS
TITLE: Method and compositions for modulating amyloid
precursor protein translation with dimercaptopropanol
and other compounds
INVENTOR(S): Rogers, Jack; Payton, Sandra; Gullans, Steve; Randall,
Jeff; Sarang, Satinder
PATENT ASSIGNEE(S): The General Hospital Corporation, USA; The Brigham and
Women's Hospital, Inc.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112700	A2	20041229	WO 2004-US18158	20040607
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

=> dup rem l38 l61

FILE 'MEDLINE' ENTERED AT 12:29:29 ON 24 JAN 2005

FILE 'EMBASE' ENTERED AT 12:29:29 ON 24 JAN 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

PROCESSING COMPLETED FOR L38

PROCESSING COMPLETED FOR L61

L62 30 DUP REM L38 L61 (0 DUPLICATES REMOVED)
ANSWERS '1-11' FROM FILE MEDLINE
ANSWERS '12-30' FROM FILE EMBASE

=> d que l62

L1	4	SEA FILE=REGISTRY ABB=ON	PLU=ON	PIOGLITAZONE?/CN
L2	3	SEA FILE=REGISTRY ABB=ON	PLU=ON	ZAFIRLUKAST?/CN
L3	0	SEA FILE=REGISTRY ABB=ON	PLU=ON	SIMIVASTATIN?/CN
L4	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	ZOCOR/CN
L5	7	SEA FILE=REGISTRY ABB=ON	PLU=ON	SIMVASTATIN?/CN
L6	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	LIPITOR/CN
L7	7	SEA FILE=REGISTRY ABB=ON	PLU=ON	ATORVASTATIN?/CN
L8	2	SEA FILE=REGISTRY ABB=ON	PLU=ON	FENOFIBR?/CN
L9	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	CILOSTAZOL?
L11	24	SEA FILE=REGISTRY ABB=ON	PLU=ON	(L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9)
L27	78	SEA FILE=REGISTRY ABB=ON	PLU=ON	(107753-78-6/CRN OR 111025-46 -8/CRN OR 112529-15-4/CRN OR 121009-77-6/CRN OR 125995-03-1/CRN OR 134523-00-5/CRN OR 134523-01-6/CRN OR 134523-02-7/CRN OR 134523-03-8/CRN OR 139893-43-9/CRN OR 145350-09-0/CRN OR 151006-18-7/CRN OR 262291-01-0/CRN OR 262291-02-1/CRN OR 340266-37-7/CRN OR 344423-98-9/CRN OR 414355-31-0/CRN OR 42017-89-0/CRN OR 424787-67-7/CRN OR 468728-50-9/CRN OR 49562-28-9/CRN OR 618116-61-3/CRN OR 73963-72-1/CRN OR 79902-63-9/CRN)
L28	89	SEA FILE=REGISTRY ABB=ON	PLU=ON	L27 OR L11
L34	4163	SEA FILE=MEDLINE ABB=ON	PLU=ON	L28
L35	22046	SEA FILE=MEDLINE ABB=ON	PLU=ON	DELAYED-ACTION PREPARATIONS+PF T,NT/CT
L36	11	SEA FILE=MEDLINE ABB=ON	PLU=ON	L34 AND L35
L37	1	SEA FILE=MEDLINE ABB=ON	PLU=ON	L36 AND SOLUB?
L38	11	SEA FILE=MEDLINE ABB=ON	PLU=ON	L36 OR L37
L39	26	SEA FILE=REGISTRY ABB=ON	PLU=ON	POLYOXYETHYLENE-POLYOXYPROPYL KNE?/CN
L40	207	SEA FILE=REGISTRY ABB=ON	PLU=ON	CYCLODEXTRIN?/CN
L41	21	SEA FILE=REGISTRY ABB=ON	PLU=ON	TOCOL?
L42	372	SEA FILE=REGISTRY ABB=ON	PLU=ON	"TOCOPHEROL"
L50	15019	SEA FILE=EMBASE ABB=ON	PLU=ON	L28
L51	661	SEA FILE=EMBASE ABB=ON	PLU=ON	SUSTAINED RELEASE FORMULATION/C T
L52	774	SEA FILE=EMBASE ABB=ON	PLU=ON	SUSTAINED DRUG RELEASE/CT
L53	14338	SEA FILE=EMBASE ABB=ON	PLU=ON	SUSTAINED RELEASE PREPARATION+N T/CT
L54	10	SEA FILE=EMBASE ABB=ON	PLU=ON	EXTENDED RELEASE FORMULATION/CT
L56	160	SEA FILE=EMBASE ABB=ON	PLU=ON	L50 AND (L51 OR L52 OR L53 OR L54 OR (SUSTAIN? OR EXTEND? OR DELAY?) (3A)RELEAS? OR SYNCH?)
L57	32006	SEA FILE=EMBASE ABB=ON	PLU=ON	(L39 OR L40 OR L41 OR L42)
L58	7778	SEA FILE=EMBASE ABB=ON	PLU=ON	SOLUBILIZER+NT/CT
L59	190527	SEA FILE=EMBASE ABB=ON	PLU=ON	FATTY ACID+NT/CT
L60	8320	SEA FILE=EMBASE ABB=ON	PLU=ON	FATTY ACID ESTER+NT/CT

L61 19 SEA FILE=EMBASE ABB=ON PLU=ON L56 AND (L57 OR L58 OR L59 OR
L60 OR SOLUBILIZ?)
L62 30 DUP REM L38 L61 (0 DUPLICATES REMOVED)

=> d l62 ibib abs hitind 1-30

L62 ANSWER 1 OF 30 MEDLINE on STN
ACCESSION NUMBER: 2004182731 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15078639
TITLE: New perspectives on the use of niacin in the treatment of
lipid disorders.
AUTHOR: McKenney James
CORPORATE SOURCE: National Clinical Research and Virginia Commonwealth
University, Richmond, USA.. jmckenney@ncrinc.net
SOURCE: Archives of internal medicine, (2004 Apr 12) 164 (7)
697-705. Ref: 83
Journal code: 0372440. ISSN: 0003-9926.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200405
ENTRY DATE: Entered STN: 20040414
Last Updated on STN: 20040528
Entered Medline: 20040527

AB Therapy with niacin (nicotinic acid) is unique in that it improves all lipoprotein abnormalities. It significantly reduces low-density lipoprotein cholesterol, triglyceride, and lipoprotein(a) levels, while increasing high-density lipoprotein cholesterol levels. This makes niacin ideal for treating a wide variety of lipid disorders, including the metabolic syndrome, diabetes mellitus, isolated low high-density lipoprotein cholesterol, and hypertriglyceridemia. Niacin-induced changes in serum lipid levels produce significant improvements in both coronary artery disease and clinical outcomes. Niacin is currently available in 3 formulations (immediate release, extended release, and long acting), which differ significantly with respect to their safety and efficacy profiles. Immediate-release niacin is generally taken 3 times a day and is associated with adverse flushing, gastrointestinal symptoms, and elevations in blood glucose levels. Long-acting niacin can be taken once daily and is associated with significantly reduced flushing, but its metabolism increases the risk of hepatotoxic effects. Extended-release niacin, also given once daily, has an absorption rate intermediate between the other formulations and is associated with fewer flushing and gastrointestinal symptoms without increasing hepatotoxic risk.

CT Check Tags: Human

Antilipemic Agents: AE, adverse effects
Antilipemic Agents: PD, pharmacology
*Antilipemic Agents: TU, therapeutic use
Delayed-Action Preparations
Dose-Response Relationship, Drug
Drug Therapy, Combination
Hyperlipidemia: CO, complications
*Hyperlipidemia: DT, drug therapy
Lipoproteins, HDL Cholesterol: DE, drug effects
Lipoproteins, LDL Cholesterol: DE, drug effects
Niacin: AE, adverse effects